Valuation : Processa Pharmaceuticals, Inc.

Market Cap 5.75M 4.95M 4.65M 4.25M 7.95M 544M 7.97M 55.19M 21.33M 279M 21.61M 21.14M 888M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value 217K 187K 176K 161K 300K 20.56M 301K 2.09M 806K 10.53M 816K 799K 33.54M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.18%
Yield 2024 *
-
Yield 2025 -

Last Transcript : Processa Pharmaceuticals, Inc.

1 day+0.49%
1 week+0.49%
Current month+0.49%
1 month-19.84%
3 months-18.25%
6 months-27.21%
Current year-28.47%
1 week 2.01
Extreme 2.01
2.18
1 month 2
Extreme 2
2.79
Current year 1.67
Extreme 1.6701
3.8
1 year 1.67
Extreme 1.6701
14.24
3 years 1.67
Extreme 1.6701
450
5 years 1.67
Extreme 1.6701
4,495.35
10 years 1.67
Extreme 1.6701
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 2023-08-07
Investor Relations Contact 60 2011-03-28
Chief Administrative Officer 61 2017-10-03
Director TitleAgeSince
Chairman 73 2011-03-28
Chairman 60 2022-08-15
Director/Board Member 56 2020-02-12
Date Insider Type Main position Quantity % Market Cap. Importance
8/8/26 Exercice

Chief Executive Officer

3,200 0.1156%
7/26/26 Other

Chief Financial Officer

11,883 0.4293%
7/26/26 Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%+0.49%-52.04%-98.63% 5.75M
-0.38%-2.64%+42.69%+99.03% 67.98B
-2.71%-0.71%+35.89%+81.43% 64.94B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
-1.42%-0.74%+31.24%+15.84% 25.74B
-1.11%+0.90%+22.24%-18.50% 20.09B
+1.15%-14.24%+219.82%+381.14% 17.16B
+0.20%-1.37%-6.41%+549.54% 14.92B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.34%+0.89%+32.85%+153.94% 27.91B
Weighted average by Cap. -0.81%+0.47%+37.32%+140.60%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.19M -9.59M -8.75M -16.36M -1.12B -16.42M -114M -43.93M -574M -44.5M -43.53M -1.83B -13.56M -11.66M -10.97M -10.02M -18.73M -1.28B -18.79M -130M -50.28M -657M -50.94M -49.82M -2.09B
Net Debt -1.12M -961K -904K -825K -1.54M -106M -1.55M -10.72M -4.14M -54.14M -4.2M -4.11M -172M -5.54M -4.76M -4.48M -4.09M -7.65M -524M -7.67M -53.1M -20.53M -268M -20.79M -20.34M -854M
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
26-09-04 US$2.060 +0.49% 12,344
26-09-03 US$2.050 -2.38% 10,301
26-09-02 US$2.100 +2.44% 12,719
26-09-01 US$2.050 0.00% 14,533

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PCSA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!